Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around

Description

Summary

Official Title

A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Keywords

Melanoma, Unresectable, Metastatic, Stage III, Stage IV, Anti-Lymphocyte-activation gene 3 Pathway (LAG-3), Pembrolizumab, Cemiplimab, Fianlimab

Eligibility

Locations

  • University of California San Diego accepting new patients
    La Jolla California 92093 United States
  • The Angeles Clinic and Research Institute accepting new patients
    Los Angeles California 90025 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Regeneron Pharmaceuticals
Links
A clinical study for adults and adolescents with advanced melanoma skin cancer.
ID
NCT05352672
Phase
Phase 3 Skin Cancer/Melanoma Research Study
Study Type
Interventional
Participants
Expecting 1535 study participants
Last Updated